Manage breakthrough bleeds with reduced doses and frequency of factor or BPA^1*†

Initially, the weight-based dose of factor or BPA should be reduced, and the dosing interval doubled compared to the standard dose¹

Qfitlia^TM prophylaxis leads to increased thrombin generation, with an additive increase in peak thrombin when used concomitantly with factor replacement or BPA.¹

^*The combined use of antifibrinolytics with factor or BPA has not been studied in clinical studies.^1
†For patients using on-demand treatment with factor or BPA after Qfitlia initiation, the prior dosing regimen of factor or BPA therapy may be used to treat breakthrough bleeding episodes only for the first 7 days.^1
‡For situations requiring higher doses, more frequent administration, or multiple repeat doses, use clinical judgment. Adjunctive management of bleeding episodes and cases of thrombosis should be carried out per standard of care.¹

If adequate hemostatic control is not achieved, higher doses may be used per clinical judgment.¹

Qfitlia has been evaluated in 60 major, and 71 minor, surgeries in people with hemophilia A or B, with or without inhibitors. Patients have undergone both major and minor surgical procedures without discontinuing Qfitlia prophylaxis in clinical studies. Bleed management guidance should be utilized during the perioperative period for hemostatic management.¹

Adherence to the bleed management guidance on the recommended dose of factor replacement or BPA may help minimize the risk of TEs while on Qfitlia.¹